Drugs / QS-21
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06417853 | Jul 2024 → Jan 2026 | avian influenza | Vaxxas Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00005632 | Jun 1999 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003224 | Feb 1996 → Aug 2000 | cutaneous melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT00001044 | ? → May 1995 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00001096 | ? → Mar 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01687595 | Oct 2012 → Sep 2013 | genital herpes simplex type 2 infectious disorder | Agenus Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00752232 | Dec 2008 → Jul 2012 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00498602 | Nov 2007 → Feb 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00003362 | May 1998 → Feb 2001 | cutaneous melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00005052 | Dec 1999 → ? | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00470574 | Mar 2007 → Jan 2020 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 24 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT06741072 Background | Jun 2026 → Jul 2027 expected | Epstein-Barr virus-associated lymphoproliferative disorder, end stage renal failure, post-transplant lymphoproliferative disease | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03673020 Background | May 2019 → Feb 2021 | cancer | Agenus Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02992977 Background | Jan 2017 → Dec 2018 | — | Agenus Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01248273 Background | Nov 2010 → Mar 2017 | fallopian tube disorder, ovarian cancer, peritoneum cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00036933 Background | Mar 2002 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00006387 Background | Oct 2000 → Jan 2002 | colorectal cancer, malignant pancreatic neoplasm | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00006041 Background | Feb 2000 → Feb 2002 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00004929 Background | Sep 1999 → Jun 2008 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00004156 Background | May 1999 → Jun 2008 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003819 Background | Jun 1998 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003357 Background | Jan 1998 → Nov 2001 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00001572 Background | Jan 1997 → Jul 1999 | follicular lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00001052 Background | ? → Sep 1997 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000809 Background | — | HIV infectious disease, seronegative autoimmune hepatitis | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05841550 Background | May 2023 → May 2027 expected | smoldering plasma cell myeloma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05638698 Background | Dec 2022 → Dec 2024 overdue | neoplasm | University of Kansas Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01227564 Background | Feb 2011 → Feb 2014 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00955409 Background | Nov 2009 → Dec 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00960531 Background | Jul 2009 → Dec 2013 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00479557 Comparator | May 2007 → Jan 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00579423 Background | Nov 2000 → May 2003 | cancer, prostate disorder | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00004052 Background | Mar 1999 → Aug 2005 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00004249 Background | Aug 1998 → Nov 2001 | small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00030823 Background | Mar 2001 → Feb 2009 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QS-21 | “The vaccines were administered s.c. in either of two adjuvants, Montanide ISA-51 or QS-21, to 22 patients with high-risk resected melanoma (stage IIB-IV).” PMID 11595689 ↗ Oct 200137“QS-21 is a naturally occurring saponin molecule purified from the South American tree Quillaja saponaria Molina.” NCT05841550 ↗ “Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18” NCT00955409 ↗ “12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)” NCT06417853 ↗ “106-amino acid-long MUC1 peptide conjugated with KLH plus immune adjuvant QS-21” PMID 11807794 ↗ Feb 2002 “ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo” NCT00960531 ↗ “with QS-21 Stimulon® adjuvant” NCT02992977 ↗ “QS-21, a saponin adjuvant” NCT06741072 ↗ “adjuvant QS-21” NCT00006041 ↗ |
| Known as | MUC1-KLH vaccine/QS21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005632 ↗ |
| Known as | QUILLAJA SAPONIN (QS-21) | “QUILLAJA SAPONIN (QS-21)” NCT06741072 ↗ |
| Known as | Stimulation-QS-21 | “QS-21 (Stimulation-QS-21) Drug” NCT00001572 ↗ |
| Known as | Stimulon | “with QS-21 Stimulon® adjuvant” NCT02992977 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00005632 ↗ |
| Modality | Vaccine | “Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.” NCT00005632 ↗ |
| Route | Subcutaneous | “The vaccine is administered with subcutaneous QS-21 as an immunological adjuvant.” NCT00001572 ↗ |
| Target | MUC1 | “response against MUC-1” NCT00005632 ↗ |